TR201904846T4 - Apolipoprotein saptamasına yönelik yöntemler. - Google Patents

Apolipoprotein saptamasına yönelik yöntemler. Download PDF

Info

Publication number
TR201904846T4
TR201904846T4 TR2019/04846T TR201904846T TR201904846T4 TR 201904846 T4 TR201904846 T4 TR 201904846T4 TR 2019/04846 T TR2019/04846 T TR 2019/04846T TR 201904846 T TR201904846 T TR 201904846T TR 201904846 T4 TR201904846 T4 TR 201904846T4
Authority
TR
Turkey
Prior art keywords
methods
detection
apolipoprotein
apolipoprotein detection
apolipoproteins
Prior art date
Application number
TR2019/04846T
Other languages
English (en)
Inventor
Rodriguez Martin Andrés
Calero Lara Miguel
Calero Rueda Olga
Garcia Albert Luis
Original Assignee
Biocross S L
Centro De Investig Biomedica En Red De Enfermedades Neurodegenerativas Ciberned
Inst De Salud Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocross S L, Centro De Investig Biomedica En Red De Enfermedades Neurodegenerativas Ciberned, Inst De Salud Carlos Iii filed Critical Biocross S L
Publication of TR201904846T4 publication Critical patent/TR201904846T4/tr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

Mevcut buluş, bir numunede apolipoproteinler ve bunların izoformlarının saptanması ve miktarının ölçülmesine yönelik yöntemler ile, bunun yanı sıra buluşun saptama yöntemleri ile belirlendiği üzere apolipoprotein seviyelerine bağlı olarak nörodejeneratif veya kardiyovasküler hastalık olasılığına yönelik tahmini yöntemler ile ilgilidir.
TR2019/04846T 2015-11-02 2016-11-02 Apolipoprotein saptamasına yönelik yöntemler. TR201904846T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15382537.7A EP3163303A1 (en) 2015-11-02 2015-11-02 Methods for apolipoprotein detection

Publications (1)

Publication Number Publication Date
TR201904846T4 true TR201904846T4 (tr) 2019-04-22

Family

ID=54608470

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/04846T TR201904846T4 (tr) 2015-11-02 2016-11-02 Apolipoprotein saptamasına yönelik yöntemler.

Country Status (16)

Country Link
US (1) US20180313854A1 (tr)
EP (3) EP3163303A1 (tr)
JP (1) JP6994718B2 (tr)
KR (1) KR102630558B1 (tr)
CN (1) CN108700593A (tr)
AU (1) AU2016348558B2 (tr)
CA (1) CA3003837A1 (tr)
DK (1) DK3274725T3 (tr)
ES (1) ES2728268T3 (tr)
HU (1) HUE042606T2 (tr)
MX (1) MX2018005448A (tr)
PL (1) PL3274725T3 (tr)
PT (1) PT3274725T (tr)
RU (1) RU2763404C2 (tr)
TR (1) TR201904846T4 (tr)
WO (1) WO2017076919A2 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017299781B2 (en) * 2016-07-21 2024-03-07 Cleveland Heartlab, Inc. HDL-associated protein biomarker panel detection
CN112689762B (zh) * 2018-06-01 2024-08-23 美国控股实验室公司 用于lc-ms/ms蛋白质组学基因分型的方法和系统
CN109212218A (zh) * 2018-11-07 2019-01-15 李玉民 基于apoa4蛋白胃癌检测试剂盒、及其使用方法
US20220326258A1 (en) * 2019-09-13 2022-10-13 Northwestern University Biomarkers for amyotrophic lateral sclerosis (als) and motor neuron diseases
CN110780071A (zh) * 2019-11-11 2020-02-11 彭涛 一种乙肝相关肝细胞癌的预后检测试剂盒
CN112375138B (zh) * 2020-11-13 2022-12-13 中元汇吉生物技术股份有限公司 一种重组载脂蛋白e和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772549A (en) * 1986-05-30 1988-09-20 Biotechnology Research Partners, Ltd. Polymorphisms related to lipid metabolism: ApoB, ApoCII, ApoE, ApoAIV
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
JP3397066B2 (ja) * 1996-12-27 2003-04-14 富士レビオ株式会社 免疫学的測定方法を用いたアポ蛋白ｅフェノタイプの同定方法
AU762931B2 (en) * 1999-03-16 2003-07-10 Serex, Inc. Method and device for detection of Apo A, Apo B and the ratio thereof in saliva
DE60225821T2 (de) * 2001-10-04 2009-04-30 Immuno-Biological Laboratories Co., Ltd., Takasaki Reagens zum Nachweis eines Risikofaktors der Alzheimer-Krankheit, Nachweiskit dafür und Verfahren zum Nachweis eines Risikofaktors der Alzheimer-Krankheit unter ihrer Verwendung
US7208481B2 (en) * 2002-02-19 2007-04-24 Ilex Products, Inc. Aminodiphosphonate apolipoprotein E modulators
US20050255498A1 (en) * 2004-01-22 2005-11-17 Genaissance Pharmaceuticals APOC1 genetic markers associated with age of onset of Alzheimer's Disease
JP5229789B2 (ja) * 2007-02-27 2013-07-03 プリマハム株式会社 新規ストレスバイオマーカー及びその用途
WO2009108073A1 (en) * 2008-02-28 2009-09-03 Auckland Uniservices Limited Biomarkers for prediction of preeclampsia and/or cardiovascular disease
ES2364169B1 (es) * 2010-02-09 2012-07-10 CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (Titular al 50%) Uso de las isoformas de apo j como biomarcadores de lesión tisular.
EP2542581A4 (en) * 2010-03-01 2014-01-22 David Gladstone Inst SPECIFIC APOLIPOPROTEIN ANTIBODY AND METHODS OF USING SAME
US20120009125A1 (en) * 2010-07-06 2012-01-12 Lombard Jay L Apoe4 and apoj biomarker-based prevention and treatment of dementia
US9494606B2 (en) * 2012-05-09 2016-11-15 President And Fellows Of Harvard College Quantification of lipoproteins
ES2759026T3 (es) * 2013-02-26 2020-05-07 Inst Oftalmologico Fernandez Vega S L Método para el diagnóstico de glaucoma basándose en la determinación de niveles de proteínas séricas

Also Published As

Publication number Publication date
BR112018008749A2 (pt) 2018-10-30
PT3274725T (pt) 2019-04-30
CN108700593A (zh) 2018-10-23
ES2728268T3 (es) 2019-10-23
US20180313854A1 (en) 2018-11-01
KR20180081545A (ko) 2018-07-16
PL3274725T3 (pl) 2019-08-30
CA3003837A1 (en) 2017-05-11
BR112018008749A8 (pt) 2019-02-26
WO2017076919A3 (en) 2017-06-15
EP3163303A1 (en) 2017-05-03
DK3274725T3 (en) 2019-04-23
HUE042606T2 (hu) 2019-07-29
RU2763404C2 (ru) 2021-12-28
AU2016348558B2 (en) 2022-02-24
EP3457140A1 (en) 2019-03-20
AU2016348558A1 (en) 2018-06-21
JP6994718B2 (ja) 2022-01-14
KR102630558B1 (ko) 2024-01-26
JP2018533022A (ja) 2018-11-08
RU2018120081A3 (tr) 2020-03-10
WO2017076919A2 (en) 2017-05-11
EP3274725A2 (en) 2018-01-31
RU2018120081A (ru) 2019-12-05
EP3274725B1 (en) 2019-01-09
MX2018005448A (es) 2019-04-04

Similar Documents

Publication Publication Date Title
TR201904846T4 (tr) Apolipoprotein saptamasına yönelik yöntemler.
EA201791578A1 (ru) Панель биомаркеров для обнаружения рака
MA40390A (fr) Procédés d'analyse impliquant des nanoparticules dissociables
BR112014031365A2 (pt) métodos de detectar doenças ou condições
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
MX2023005452A (es) Deteccion de beta amiloide por espectrometria de masas.
MX349347B (es) Enfermedad tromboembolica.
CY1122360T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
TR201907802T4 (tr) Kuantum kapasitans algılama.
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
CY1121282T1 (el) Μεθοδος ανιχνευσης της μολυνσης απο η.pylori
WO2014124174A3 (en) Circulating bmec and related cells as biomarkers of cns diseases associated with the blood-brain-barrier disorders
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
MX2022013471A (es) Metodo y composiciones de deteccion y cuantificacion de acido nucleico.
AR102037A1 (es) Procesador y método para el procesamiento de una señal de audio por el uso del análisis truncado o las porciones de solapamiento de la ventana de síntesis
EA201692497A1 (ru) Биомаркеры ответа на ингибиторы ezh2
MX2020001830A (es) Deteccion y cuantificacion de guanidinoacetato, creatina, y creatinina mediante espectrometria de masas.
MX2016009450A (es) Ensayo novedoso para detectar periostina humana.
CY1121790T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
MX363679B (es) Metodo para diagnosticar cancer.
WO2014151290A3 (en) Assay for predictive biomarkers
MX2020002787A (es) Metodo para el analisis de metilacion.
WO2020115270A3 (en) Biomarker for detecting zearalenone effect